The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank Ling et al.|Cancer Discovery|2020Cited by 26
Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapyMarco Cerrano, Raphaël Itzykson, Matthieu Duchmann et al.|Leukemia|2020Cited by 20
A multiparametric niche-like drug screening platform in acute myeloid leukemiaReinaldo Dal Bello, Raphaël Itzykson, Rathana Kim et al.|Blood Cancer Journal|2022Cited by 13
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank Ling et al.|Blood|2019Cited by 5
Figure S6 from The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank W. Ling et al.|Unknown|2023Cited by 0